Camrelizumab Combined With Apatinib 、XELOX 、RFA in the Treatment of Liver Metastases of Colorectal Cancer

Sponsor
Zhongshan Hospital Xiamen University
Study ID
NCT04202978
Phase
PHASE1/PHASE2
Status
Unknown

Conditions

  • Hepatic Metastasis of Colorectal Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Camrelizumab — DRUG
    Camrelizumab ：200mg intravenous injection d1 q3w
  • Apatinib Mesylate — DRUG
    Apatinib：250mg/d P.O ,qd ,3weeks
  • Capecitabine — DRUG
    capecitabine:850mg/m2 P.O ,bid ,d1-d14
  • Oxaliplatin — DRUG
    oxaliplatin:130mg/m2 intravenous injection d1 q3w
  • radiofrequency ablation — RADIATION
    radiofrequency ablation:between first cycle and second cycle percutaneous

Study Details

To evaluate the safety of karillizumab combined with apatinib mesylate, XELOX and radiofrequency ablation

Key Dates

Start date
Mar 1, 2020
Status verified
Feb 2020
Primary completion
Mar 1, 2021
Completion
Nov 1, 2021

Study Design

Enrollment
23 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Camrelizumab+ Apatinib +XELOX +RFA
    Camrelizumab combined with Apatinib 、XELOX 、RFA in the treatment of liver metastases of colorectal cancer

Primary Outcome Measure

R0 resection rate [ Time Frame: 6 months ]

Central Contacts